Last reviewed · How we verify
NCT06772987
NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient
NA trial testing Accelerated rTMS treatment in Major Depressive Disorder (MDD) in 50 participants. Completed in 6 May 2025.
6 May 2025
Quick facts
| Lead sponsor | NeuroQore Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 16 January 2025 |
| Primary completion | 6 May 2025 |
| Estimated completion | 6 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Accelerated rTMS treatment
Conditions studied
- Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →
Sponsor
NeuroQore Inc.
Who can join
Adults 22 to 85, any sex, with Major Depressive Disorder (MDD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD). Currently established therapy uses one 19-minute treatment session per day for 5 days per week for 6 weeks, for a total of 30 treatment sessions. The goal of this clinical trial is to evaluate the safety and effectiveness of an accelerated but shortened TMS dosing regimen for adults with MDD aged 22-85. Participants in this study will be subjected to the same 19-minutes treatment session, but three times on the same day, and only for one day. This will greatly reduce the logistical burden of completing the therapy regime.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06772987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Disorder (MDD)
Currently open trials in the same condition.
- NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
- NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
- NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
- NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
- NCT07294924 — Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06772987 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NeuroQore Inc.
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06772987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing